A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country wher
Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health Organization (WHO) to declare a public health emergency.
Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.
The United Nations Children's Fund (UNICEF) has issued an emergency tender to secure mpox vaccines for countries dealing with the brunt of the outbreak, in collaboration with the Gavi vacci
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year